|
Clinical Trial of Small Intestinal Submucosa Absorbable Bio-films in Reconstruction of Alveolar Bone and/or Soft Tissues.
JU Jia, LIU Yuhua, ZHAO Jizhi, ZHAO Jihong, LI Hongwei, WANG Baoyan, WANG Hu, ZHANG Huan, FENG Bin, HU Kaijin
2022, 38(9):
848-853.
DOI: 10.13701/j.cnki.kqyxyj.2022.09.011
Objective: To evaluate the efficacy and safety of small intestinal submucosa (SIS) absorbable biofilms in reconstructing alveolar bone and/or soft tissue. Methods: Randomized, single-bind, parallel-control, multicenter, non-inferiority trial design was used. The main measures were the changes of the maximum length, height, and width in alveolar bone 0 and 180 days after operation. Secondary measures included changes in alveolar bone hyperplasia and resorption, changes in alveolar bone matrix marginal line, damage of biofilm, surgical incision healing, rejection reaction, and post-filling symptoms. The safety of SIS absorbable biofilms was evaluated by frequency and severity of adverse events. Results: A total of 280 cases were included in this study. Two hundred and seventy-two cases completed the trial and the abscission rate was 2.86% (8 cases). The imaging effective rate of FAS (PPS) after 180 days was 83.57% (91.34%) in the experimental group and 81.43% (92.62%) in the control group, and 95%CI was 2.14% (-6.75%, 11.04%) in FAS and -1.28% (-8.03%, 5.46%) in PPS (P>0.05). The changes of alveolar bone growth and resorption, alveolar bone matrix marginal line, experimental membrane damage 12 days after surgery, clinical incision healing, rejection reaction, and filling status of each visiting point had no significant differences between two groups (P>0.05). The incidence of adverse events and serious adverse events during the treatment had no significant difference (P>0.05). Conclusion: SIS absorbable biofilms were non-inferior to Bio-Gide absorbable biofilms in reconstructing alveolar bone and/or soft tissue.
References |
Related Articles |
Metrics
|